Guidelines for the management of myeloproliferative neoplasms
The Korean Journal of Internal Medicine
; : 771-788, 2015.
Article
in En
| WPRIM
| ID: wpr-92366
Responsible library:
WPRO
ABSTRACT
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as 'Philadelphia-negative classical myeloproliferative neoplasms (MPNs).' The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new target for drug development. The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate- to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials. In 2011, the Korean Society of Hematology MPN Working Party devised diagnostic and therapeutic guidelines for Korean MPN patients. Subsequently, other genetic mutations have been discovered and many kinds of new drugs are now under clinical investigation. In view of recent developments, we have revised the guidelines for the diagnosis and management of MPN based on published evidence and the experiences of the expert panel. Here we describe the epidemiology, new genetic mutations, and novel therapeutic options as well as diagnostic criteria and standard treatment strategies for MPN patients in Korea.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Signal Transduction
/
Risk Factors
/
Treatment Outcome
/
Asian People
/
Protein Kinase Inhibitors
/
Janus Kinase 2
/
Republic of Korea
/
Molecular Targeted Therapy
/
Mutation
/
Myeloproliferative Disorders
Type of study:
Clinical_trials
/
Etiology_studies
/
Guideline
/
Risk_factors_studies
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
The Korean Journal of Internal Medicine
Year:
2015
Type:
Article